Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well eribulin mesylate (E7389; Halichondrin B Analog)
works in treating patients with metastatic prostate cancer that did not respond to hormone
therapy. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.